SecSonar.com

Insmed Incorporated (INSM)

Insmed Incorporated at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Insmed Incorporated (INSM) is a Biotechnology company based in US with a market capitalization of $23.3B. Revenue grew 66.7% year-over-year and free cash flow was negative at -$967.6M. This page tracks INSM's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 1.27K employees · IPO Jun 1, 2000

Valuation

Valuation & price

$109.14 · as of May 17, 2026 · -48.4% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

31.58

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$209$150$91.88Jul 25Dec 25Jun 26Jul 7, 25$96.95Jul 9, 25$96.47Jul 11, 25$98.18Jul 15, 25$102.87Jul 17, 25$104.17Jul 21, 25$102.78Jul 23, 25$103.44Jul 25, 25$103.95Jul 29, 25$105.00Jul 31, 25$107.28Aug 4, 25$111.24Aug 6, 25$111.26Aug 8, 25$109.55Aug 12, 25$122.00Aug 14, 25$127.75Aug 18, 25$127.27Aug 20, 25$129.45Aug 22, 25$131.88Aug 27, 25$134.53Aug 29, 25$136.10Sep 3, 25$143.50Sep 5, 25$145.10Sep 9, 25$147.20Sep 11, 25$145.79Sep 15, 25$143.14Sep 17, 25$144.78Sep 19, 25$144.76Sep 23, 25$145.38Sep 25, 25$135.59Sep 29, 25$141.65Oct 1, 25$147.28Oct 3, 25$157.16Oct 7, 25$162.32Oct 9, 25$164.40Oct 13, 25$163.94Oct 16, 25$163.19Oct 20, 25$167.91Oct 22, 25$160.40Oct 24, 25$159.66Oct 28, 25$165.29Oct 30, 25$194.22Nov 3, 25$186.23Nov 5, 25$186.88Nov 7, 25$189.70Nov 11, 25$193.69Nov 13, 25$190.96Nov 17, 25$197.40Nov 19, 25$203.56Nov 21, 25$198.76Nov 25, 25$209.02Nov 28, 25$207.77Dec 2, 25$206.60Dec 5, 25$204.00Dec 9, 25$194.17Dec 11, 25$195.24Dec 15, 25$196.92Dec 17, 25$198.46Dec 19, 25$174.84Dec 23, 25$176.77Dec 26, 25$177.88Dec 30, 25$174.09Jan 2, 26$177.12Jan 6, 26$175.07Jan 8, 26$170.27Jan 12, 26$167.72Jan 14, 26$163.46Jan 16, 26$161.42Jan 21, 26$156.32Jan 23, 26$156.21Jan 28, 26$155.89Jan 30, 26$156.87Feb 3, 26$157.16Feb 5, 26$151.03Feb 9, 26$149.54Feb 11, 26$148.43Feb 13, 26$148.75Feb 18, 26$151.11Feb 20, 26$164.91Feb 24, 26$158.62Feb 26, 26$150.00Mar 2, 26$146.32Mar 4, 26$149.88Mar 6, 26$140.13Mar 10, 26$143.85Mar 12, 26$139.52Mar 16, 26$144.60Mar 19, 26$144.00Mar 23, 26$143.98Mar 25, 26$148.31Mar 27, 26$145.30Mar 31, 26$163.52Apr 2, 26$162.43Apr 7, 26$163.03Apr 9, 26$159.59Apr 13, 26$151.14Apr 15, 26$146.74Apr 17, 26$144.48Apr 21, 26$140.98Apr 23, 26$143.83Apr 27, 26$135.98Apr 29, 26$135.03May 1, 26$133.26May 5, 26$139.44May 8, 26$101.35May 12, 26$116.00May 14, 26$115.62May 18, 26$107.15May 20, 26$107.91May 22, 26$106.24May 27, 26$106.40May 29, 26$106.91Jun 2, 26$103.73Jun 4, 26$104.92Jun 8, 26$94.17Jun 10, 26$91.88Jun 12, 26$97.85Jun 16, 26$95.52Jun 18, 26$95.80Jun 23, 26$102.15Jun 29, 26$104.23
$91.8852-week range$211.41
Loading valuation history…

Fundamentals

Key fundamentals

$23.3B

Market cap

66.7%

Revenue growth (YoY)

79.4%

Gross margin

-$967.6M

Free cash flow (USD)

-$661.9M

Net debt

Net cash position

30.2%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$9.8MFY 2019$136.5MFY 2020$164.4MFY 2021$188.5MFY 2022$245.4MFY 2023$305.2MFY 2024$363.7MFY 2025$606.4M
$0$606.4M

Free cash flow by year

2016 → 2025

FY 2016$-150.9MFY 2017$-162.6MFY 2018$-272.8MFY 2019$-292.9MFY 2020$-226.2MFY 2021$-370.6MFY 2022$-410.3MFY 2023$-549.5MFY 2024$-705.8MFY 2025$-967.6M
-$150.9M-$967.6M

Gross margin by year

2021 → 2025

FY 202176.6%FY 202277.5%FY 202378.5%FY 202476.4%FY 202579.4%
76.6%79.4%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsMay 15, 2026Filing
  • FinancingSecurities RegistrationMay 15, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • 8-K eventClinical Study ResultsApr 7, 2026Filing

Questions

Frequently asked questions

What is Insmed Incorporated's market cap?

Insmed Incorporated (INSM) has a market capitalization of $23.3B.

What is INSM's P/E ratio?

A meaningful P/E ratio is not available for INSM — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is INSM's price-to-book (P/B) ratio?

INSM trades at 31.58 times book value per share.

Are insiders buying INSM stock?

SEC Form 4 filings show no open-market insider buys at Insmed Incorporated in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

UTHR

United Therapeutics Corporation

$23.4B

RPRX

Royalty Pharma plc

$23.6B

ROIV

Roivant Sciences Ltd.

$21.7B

INCY

Incyte Corporation

$19.5B

MRNA

Moderna, Inc.

$19.3B

GMAB

Genmab A/S

$16.3B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.